System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 10 citations

PubMed: 37873626 DOI: 10.3346/jkms.2023.38.e314

Effectiveness and Safety of COVID-19 Vaccination During Preconceptional and Preclinical Pregnancy Period: A National Population Study.

J Korean Med Sci 38(41):e314

Authors: Eunseon Gwak, Taemi Kim, Ju-Young Shin, Nam-Kyong Choi, Seungbong Han, Ji Yeon Lee, Young June Choe, Seung-Ah Choe

Affiliations

  • Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.
  • Department of Public Health, Korea University, Seoul, Korea.
  • Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
  • Department of Health Convergence, College of Science and Industry Convergence, Ewha Womans University, Seoul, Korea.
  • Department of Biostatistics, Korea University College of Medicine, Seoul, Korea.
  • Department of Obstetrics & Gynecology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
  • Department of Pediatrics, Korea University Anam Hospital, Seoul, Korea.
  • Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.

Abstract

BACKGROUND

We aimed to assess the risk of maternal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and early abortive outcomes after the association between coronavirus disease 2019 (COVID-19) vaccination during the preconceptional period and preclinical pregnancy, which are likely to be inadvertent vaccination.

METHODS

We used data from the Korea Disease Control and Prevention Agency-COVID19-National Health Insurance Service cohort from December 2020 to December 2021. The vaccinated pregnant women were matched to unvaccinated pregnant controls at a 1:4 ratio. The risks of SARS-CoV-2 infection and intensive care unit (ICU) admission within 14 days of infection were analyzed to assess its effectiveness. For safety measures, the adjusted relative risks (aRRs) of early abortive outcomes for the first COVID-19 vaccination during the preconceptional and preclinical periods were calculated considering covariates. We compared the risk of early abortion between mRNA and viral vector vaccines.

RESULTS

The overall COVID-19 vaccination rates during the preconceptional period and preclinical pregnancy were 3.1% (6,662/215,211) and 2.6% (5,702/215,211), respectively. The cumulative incidence of ICU admission within 14 days of SARS-CoV-2 infection was 6/100,000 in the unvaccinated group, whereas there were no ICU admissions in the vaccinated groups. The risks of early abortive outcomes were not significantly different between the preconceptional vaccination group and the unvaccinated group (aRR, 1.04; 95% confidence interval [CI],0.99-1.10) or between preclinical pregnancy vaccination and their matched controls (1.02; 95% CI, 0.96-1.08). mRNA and viral vector vaccines have shown similar risks for early abortive outcomes and miscarriages.

CONCLUSION

Our findings have provided compelling evidence regarding the effectiveness and safety of COVID-19 vaccination prior to and during early pregnancy. Further research is required to extend the safety and efficacy profiles of COVID-19 vaccines to pregnant women and their babies.

MeSH

Pregnant Women, Coronavirus, Pregnancy, Sars-Cov-2, Safety, Vaccines, Vaccination, Covid-19, Intensive Care Units, Infections

Cited by